In this work we describe, for first time, that high activation levels of the TGFβ pathway in epithelial ovarian cancers contributes to tumor ovarian cell proliferation by stimulating IGF1R expression. Our results have been obtained using orthotopic models of these tumors, human patient samples and ovarian tumoral cells, and lead us to propose the use of TGFβ inhibitors as an alternative to the use of IGF1R inhibitors for the treatment of epithelial ovarian cancers.
INTRODUCTION
Ovarian cancer is the second most common gynecological cancer by incidence (≈6 per 100,000 individuals) and the fifth most common cause of cancer death in women in western countries 1 . More than 90% of ovarian tumors have an epithelial origin and can be classified into four main histological types: high-grade serous (70% of cases; the more aggressive type), endometrioid, mucinous and clear cell tumors 2 . Although progress has been made in the treatment of this cancer by improved surgical debulking and the introduction of platinum-taxane regimens of chemotherapy, the overall 5-year survival rate is only 29% in advanced-stage disease (80% of cases). This low survival rate is mainly because of intrinsic and acquired resistance to platinum-based chemotherapy 1, 3 . Together, these observations highlight the importance of having a more detailed understanding of potential new targets.
A good candidate is the Transforming Growth Factor Beta (TGFβ) signaling pathway. TGFβs members (formed by TGFβ1, 2 and 3) signal through binding to their membrane serine/threonine kinase receptors TGFβRII and I, phosphorylation of intracellular effectors Smad2 and Smad3, formation of heterodimers phosphoSmad2/3 with Smad4, translocation to the nucleus and regulation of gene transcription 4, 5 . TGFβ members play a role as inhibitors of normal epithelial and endothelial cell proliferation, but they contribute to cancer progression in later stages. This dual role is caused by mutations that abrogate the normal cell cycle arrest caused by TGFβ members, but that maintain TGFβ−stimulation of the processes involved in cancer progression and dissemination, such as EMT transition, angiogenesis, extracellular matrix remodeling, migration and invasion [6] [7] [8] .
TGFβ plays a similar role in ovary. Thus, while TGFβ blocks cell growth in normal ovarian epithelial cells, in 40% of ovarian carcinomas TGFβ loses its cytostatic effect but maintains EMT induction and production of extracellular matrix 9 .
Considering these data from ovarian cancer cells and that treatments against TGFβ are now under clinical development [10] [11] [12] , we decided in this work to study the contribution of TGFβ to ovarian cancer progression using orthotopic models of ovarian cancer. purchased from Janvier (France). Mice were housed and maintained in laminar flow cabinets under specific pathogen-free conditions. All the animal studies were approved by the local committee for animal care (DAAM 5766).
MATERIALS AND METHODS

Chemical compounds
LY2109761
The ovarian tumors used were perpetuated in nude mice by consecutive passages.
We used three orthotopic ovarian patient-derived xenograft (PDX, also called Orthoxenografts) models. They were generated in our group by implantation into nude mice of tumor samples obtained from untreated patients after surgery. For surgical implantation mice were anesthetized by isoflurane inhalation. A small incision was made and the ovaries were exteriorized. A 6-mm 3 piece tumor was implanted in each ovary using Prolene 7.0 surgical sutures. The ovaries were returned to the abdominal cavity and the incision was closed with wound clips.
Buprex was administered i.p. to the mice (200 µl) the day of the surgical intervention and for two days after the implantation.
Treatment schedule
As the tumors had different growth behaviors the treatment schedules were different. Treatments started when a palpable intra-abdominal mass was detected; studies were terminated when tumors in vehicle-treated animals were judged to be adversely affecting their wellbeing.
Treatment of the high-grade serous tumor models OVA8 and OVA17 started 5 The rest of the methods are described in the Supplementary Materials and Methods.
RESULTS
To explore the importance of the TGFβ signaling pathway in ovarian cancer, we first performed immunohistochemical analysis for active Smad2 levels (phosphoSmad2 or pSmad2), instead of using total protein levels. We used a TMA containing 32 high-grade serous and 34 endometrioid primary tumors obtained from patients affected by these ovarian cancers. As observed in Fig. 1A , the main part of the tumors were stained for pSmad2 at high levels, all of them presenting nuclear localization as expected for active pSmad2. No differences in pSmad2
were found when comparing high-grade serous with endometrioid tumors (Fig. 1B) .
We detected high activation levels of pSmad2 in the epithelium of normal human
Fallopian tube compared with parenchymal cells (Fig. 1C) . These epithelial cells are mainly the origin of epithelial high-grade serous tumoral ovarian cells 15, 16 , indicating that these tumoral cells maintain a pathway that is already active in normal physiology.
The previous results prompted us to investigate the role of the TGFβ pathway for ovarian cancer progression in both tumors subtypes in greater depth.
To this end we used orthotopic pre-clinical models generated after implantation in nude mice of tumors samples obtained from patients after surgery (PDX or orthoxenografts), two high-grade serous ovarian tumors (OVA8 and OVA17) and OVA15, an endometrioid ovarian tumor model. We confirmed the results of high pSmad2 levels in normal epithelial cells from human samples in those of normal mouse Fallopian tube (Fig. 1C) . We also observed that the PDX orthotopic models presented a high degree of nuclear pSmad2 staining, very similar to the expression pattern found in primary tumors (Fig. 1C) .
In order to block activation of the TGFβ pathway in these models we measured the effect of an inhibitor of TGFβRI and II kinase activity, LY2109761 (Fig. 2B) . Surprisingly, the LY2109761 treatment only inhibited tumor growth; it had no effect on the capacity of the tumor to disseminate to other organs ( Supplementary Fig. 1A ).
The above results prompted us to determine how LY2109761 reduced tumor volume. We focused our study on OVA17 tumor samples as it was the one with the most statistically significant reduction in tumour volume. Our results showed that tumor size reduction was not due to an increase in apoptosis or necrosis ( Supplementary Fig. 1B and C) , ruling out the possibility of an effect of the treatment increasing cell death, or to changes in angiogenesis ( Supplementary Fig.   1D ). Subsequently, we examined whether cell proliferation became blocked by inhibition of the TGFβ pathway. With this objective, sections of control and treated tumor samples from OVA17 were stained with Ki67. LY2109761 treatment caused a significant decrease in the proliferation rate (Fig. 2C ). This effect on proliferation was also observed in the other tumoral models (OVA8 and OVA15, Fig. 2C ). To confirm this effect we analyzed several proteins and signaling pathways involved in the control of cell proliferation. We did not detect any change in active or total AKT levels when comparing samples from control and LY2109761-treated OVA17 tumors ( Fig. 2D and Supplementary Fig. 2A ). In contrast, active ERK1/2 levels were decreased by 38% with LY2109761 treatment (Fig. 2D and Supplementary   Fig. 2B ). This effect was also observed in OVA8 treated tumors ( Supplementary   Fig. 2B ). Next we checked proteins directly involved in cell cycle progression. We found no change in p21 or Cyclin A, although an increase in p16 (70%) and in ECadherin (350%) protein levels were noted ( Fig. 2E and Supplementary Fig. 2C and 2D). In contrast, Cyclin D1 levels (measured by immunohistochemistry) were decreased by 60% in tumors treated with LY2109761 (Fig. 2F ).
As the TGFβ signaling pathway by itself is not a classical stimulator of cell proliferation, we thought that this effect could be mediated by a different factor that is regulated by TGFβ. Equivalent mechanisms have already been described, for International Journal of Cancer compartments (Fig. 3C) . We used our TMA containing samples from various patients affected by ovarian cancers to analyze IGF1R expression. As seen in Fig.   3D , and similarly to the pSmad2 staining, the main part of the tumors presented high levels of IGF1R. More strikingly, we found a significant correlation between the levels of pSmad2 and IGF1R in the same serous tumor (Fig. 3E) . These results indicate that IGF1R expression is dependent on the activation of the TGFβ-Smad2
pathway.
Next, we decided to study the importance of IGF1R in our ovarian tumor cancer models. To this end, we treated OVA17 tumors with IMC-A12
(Cixutumumab), a monoclonal antibody against IGF1R that blocks the activity of The question arises as to how the TGFβ pathway affects IGF1R levels. To answer this first we measured IGF1R mRNA levels in the various treated and untreated orthotopic tumors. As observed in Fig. 5A , LY2109761 treatment caused a decrease in IGF1R mRNA levels in OVA8 and OVA15 tumors, while no effect was observed in OVA17, implying that several TGFβ-stimulated mechanisms control IGF1R levels. Next, we used cell culture ovarian tumoral models to analyze for IGF1R expression and TGFβ stimulation. Of the cell lines analyzed, the A2780
and OV90 ovarian serous cell types responded well to TGFβ stimulating Smad3 phosphorylation, effect that was inhibited by LY2109761 ( Fig. 5B and Supplementary Fig. 4A ). We evaluated in these cells the effect of LY2109761
inhibitor on cell viability. Addition of LY2109761 caused a dose-response inhibition in the number of viable cells ( Fig. 5C and Supplementary Fig. 4B ). We also incubated cells in the presence of IMC-A12 antibody. Results also indicated a reduction in cell viability caused by IMC-A12 incubation, similar results to the obtained in tumors. We measured IGF1Rβ protein levels in A2780 cells treated for 24 h with TGFβ or LY2109761. TGFβ caused a 100% increase in IGF1Rβ levels, while LY2109761 treatment caused a 23% decrease in this protein (Fig. 5D) .
Analysis of mRNA expression of members of the IGFs signaling pathway (e.g.,
IGF1, IGF1R and IGF1 binding proteins) revealed a TGFβ stimulation and
LY2109761 inhibition of IGF1R mRNA levels in A2780 cells (Fig. 5E ). Overall, these results suggest a transcriptional mechanism involved in controlling IGF1R levels, which is consistent with the results obtained from OVA8 and OVA15 orthotopic tumor models.
A further question arises as to how important IGF1R is in the observed
LY2109761-effect. To address this issue, we inhibited IGF1R expression in A2780
and OV90 cells. By transducing lentiviral vectors expressing either IGF1R-shRNAs or a negative control using a non-silencing vector, A2780-or OV90-NS and A2780-or OV90-shIGF1R cells were generated. We used three independent shRNA vectors. Two of them (shV2-71 and shV2-72) reduced IGF1Rβ protein expression by 70-90% ( Fig. 6A and Supplementary Fig. 4C ), while the shV2-48 vector only reduced expression by 30%. This IGF1Rβ protein depletion caused a reduction in pERK1/2 levels ( Fig. 6A and Supplementary Fig. 4C ). As shown in Fig. 4D ).
DISCUSSION
Our results show that TGFβ plays an important role in proliferation of epithelial ovarian tumoral cells through the positive regulation of IGF1R protein levels. An active TGFβ signaling pathway is characteristic of later stages of tumoral proliferation, as in squamous cell carcinomas 23 or gliomas 19 . In these latter tumors, high pSmad2 is correlated with poor prognosis. For this reason, different targeted drugs have been developed against this pathway, some of which are currently in clinical trials [10] [11] [12] . It has recently been described that in advanced serous ovarian cancers pSmad2 staining is also correlated with poor patient outcome Each data point represents the mean and SEM of five independent determinations.
Differences between control and treated cases were considered statistically significant when p < 0.05 (*) or p < 0.01 (**) (two-tailed Mann-Whitney U test). 
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